Navigation Links
New treatment offers hope for short-bowel syndrome patients
Date:7/18/2013

Bethesda, MD (July 18, 2013) A new drug, teduglutide, offers significant relief for patients with short-bowel syndrome intestinal failure who are reliant on intravenous nutrition, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. Patients with this relatively rare condition experience massive bowel loss and are unable to absorb nutrients, vitamins and water from digested foods. They rely on parenteral nutrition, or intravenous feeding, to deliver their daily nutrients.

"Short-bowel syndrome is a devastating condition, and without parenteral nutrition patients would not survive. However, this treatment method is labor-intensive, expensive and carries complications, including chronic infection, blood clots and liver failure," said Stephen J. D. O'Keefe, MD, MSc, FRCP, Division of Gastroenterology, University of Pittsburgh Medical School, PA, and lead study author. "Teduglutide, a new form of therapy, offers potential to significantly reduce intravenous nutrition dependency and improve the quality of life for patients."

Teduglutide is an injection administered once daily that helps improve intestinal absorption of fluids and nutrients, reducing the frequency and volume of parenteral nutrition.

Dr. O'Keefe and colleagues conducted a year-long trial to determine the safety, tolerability and clinical efficacy of teduglutide on patients with short-bowel syndrome. After 52 weeks, 68 percent of patients on just a low dose of teduglutide experienced lessened parenteral nutrition dependency and there was a greater than 20 percent reduction in IV-fluid requirements.

Remarkably, the study documented multiple patients who received complete independence from parenteral nutrition. These findings instill hope that short-bowel syndrome patients can achieve a significantly enhanced quality of life, free of sleep disturbances and limited social activities.

Teduglutide recently received FDA approval for individuals with short-bowel syndrome who are dependent on parenteral nutrition or intravenous therapy despite optimal medical management. There are no contraindications and no time limit on therapy. Physicians planning to prescribe the drug need to be knowledgeable in its use and potential side effects, which include gastrointestinal symptoms (abdominal pain, nausea, vomiting), headache and common cold-like symptoms. Further studies are needed to assess teduglutide's safety and efficacy long term.


'/>"/>

Contact: Rachel Steigerwald
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Related biology news :

1. Molecular discovery puts cancer treatment in a new perspective
2. Which Prostate Cancers Really Need Treatment?
3. Lifesaving HIV treatment could reach millions more people following landmark study
4. Continued research needed on treatment for women with lung cancer who are never smokers
5. Artificial sweetener a potential treatment for Parkinsons disease
6. Posttraumatic stress disorder treatment: Genetic predictor of response to exposure therapy
7. Scientists identify potential drug target for treatment-resistant anemias
8. Neurochemical traffic signals may open new avenues for the treatment of schizophrenia
9. Addition of bevacizumab to initial treatment for brain tumors does not extend patients lives
10. Engineered stem cell advance points toward treatment for ALS
11. Using big data to identify prostate cancers and best treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , ... today it has seen a third consecutive year of ... sensor technology in 2016 with a 360 percent increase ... year. This increase was driven by sales of its ... robust interest in its technology for hearables for fitness ...
(Date:12/2/2016)... 2016 The report "Biometric Vehicle ... Technology (Iris Recognition System), Vehicle Type (Passenger Car, ... to 2021", published by MarketsandMarkets, the market is ... and is projected to grow to USD 854.8 ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH ... new partnership initiative targeting national brands, industry thought-leaders ... reward their respective audiences for taking steps to ... its inception in 2012, higi has built the ... impacting over 38 million people who have conducted ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... ... December 06, 2016 , ... The ... asking the Federal Drug Administration (FDA) to consider OA as a serious disease. ... concerned about the growing population of OA patients, many of whom may experience ...
(Date:12/6/2016)... According to a new market research report ... Silicon), Application (Genomics, Proteomics, Capillary Electrophoresis, POC, Clinical, Environmental, Drug Delivery) ... is projected to reach USD 8.78 Billion by 2021 from USD ... forecast period (2016 to 2021). Continue ... ...
(Date:12/6/2016)... ... December 06, 2016 , ... ProMIS ... of precision treatments for neurodegenerative diseases, today announced the validated monoclonal antibody ... direct neurotoxic effect of prion-like forms of Amyloid beta (Aß) in vitro. ...
(Date:12/5/2016)... DENVER, COLORADO (PRWEB) , ... December 05, 2016 ... ... podcast series hosted by one of the nation’s premier cannabis technology and application ... the founder and CEO of Cultivate Colorado. Over the past 30 years, Chip ...
Breaking Biology Technology: